publication venue for
- Pleural effusion in a patient with metastatic gastrointestinal stromal tumor treated with imatinib: case report. 2014
- Clinical outcomes and healthcare resource use in triple-class exposed patients with relapsed/refractory multiple myeloma.. 21. 2025
- Patient preferences for attributes of bispecific antibodies for relapse/refractory diffuse large B-cell lymphoma in the US. 2025
- EA1211: interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy (DIRECT trial). 2025
- A plain language summary of the TROPHY-U-01 study (Cohort 2): use of sacituzumab govitecan after immunotherapy in people with metastatic urothelial cancer who cannot take cisplatin-based chemotherapy.. 21. 2025
- A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML. 2025
- A multi-perspective study assessing Black and African American participation barriers in prostate cancer clinical trials.. 21. 2025
- Safety of pressurized intraperitoneal aerosolized chemotherapy in biliary cancer patients with peritoneal metastases.. 20. 2024
- The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11 + 17/18 mutations.. 20. 2024
- T cell-inflamed gene expression profile and PD-L1 expression and pembrolizumab efficacy in advanced esophageal cancer. 2022
- KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma.. 17. 2021
- Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer.. 17. 2020
- First-line immunotherapy versus targeted therapy in patients with BRAF-mutant advanced melanoma: a real-world analysis.. 17. 2020
- Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases.. 16. 2020
- Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer.. 16. 2019
- KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer.. 15. 2019
- A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale.. 13. 2016
- Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia.. 12. 2016
- A case for the use of receiver operating characteristic analysis of potential clinical efficacy biomarkers in advanced renal cell carcinoma.. 12. 2015
- Desmoplastic small round cell tumor 20 years after its discovery.. 11. 2015
- Best of International Stereotactic Radiosurgery Society Congress 2013: stereotactic body radiation therapy. Part I: spinal tumors.. 9. 2013
- Best of International Stereotactic Radiosurgery Society Congress 2013: stereotactic body radiation therapy. Part II: nonspinal tumors.. 9. 2013
- Adipose-derived stem cells promote lymphangiogenesis in response to VEGF-C stimulation or TGF-β1 inhibition.. 7. 2011
- A plain language summary of the TROPHY-U-01 study: sacituzumab govitecan use in people with locally advanced or metastatic urothelial cancer.. 20. 2024
- Long-term benefit of sotorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: plain language summary.. 20. 2023
- Nanomolecular targeting of dendritic cells for ovarian cancer therapy.. 5. 2009
- Tumor microenvironment of metastasis (TMEM): a novel tissue-based assay for metastatic risk in breast cancer.. 5. 2009
- Talking to patients about biosimilars. 2018
- Current advances in targeted therapies for metastatic gastric cancer: improving patient care. 2016
- Imaging assessment of tumor response: past, present and future. 2011
- High-risk prostate cancer: the role of radical prostatectomy for local therapy. 2011
- Fatty acid synthase as a potential therapeutic target in cancer. 2010
- Prostate cancer: psychosocial implications and management. 2008
- Current and future surgical approaches in the management of endometrial carcinoma. 2008
- Focal therapy for oligometastatic and oligoprogressive renal cell carcinoma: a narrative review. 2024
- Cerebrospinal fluid-administered therapies for leptomeningeal metastases from solid tumors. 2023
- Androgen deprivation therapy with chemotherapy or abiraterone for patients with metastatic hormone-naive prostate cancer: a systematic review and meta-analysis. 2019
- Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma. 2018
- Immune checkpoint blockade in advanced hepatocellular carcinoma: an update and critical review of ongoing clinical trials. 2018
- A critical review on ramucirumab in the treatment of advanced urothelial cancer. 2017
- Treatment of soft tissue sarcoma: a focus on earlier stages. 2017
- Imaging of local recurrence in prostate cancer. 2016
- Novel approaches to imaging basal cell carcinoma. 2015
- Role of MRI in the diagnosis and management of prostate cancer. 2015
- Radiation-induced coronary artery disease: a second survivorship challenge? 2015
- Radiogenomics: the search for genetic predictors of radiotherapy response. 2014
- Emerging applications of stereotactic body radiotherapy. 2014
- Tissue engineering and regeneration of lymphatic structures. 2013
- Stereotactic body radiation therapy for prostate cancer. 2011
- Predictive markers of colorectal cancer liver metastases. 2011
- Dose-dense chemotherapy for breast cancer: what does the future hold? 2010
- Roles of LPA in ovarian cancer development and progression. 2009
- Clinical states model for biomarkers in bladder cancer. 2009
- Update on nuclear medicine imaging of neuroendocrine tumors. 2009
- Percutaneous renal cryoablation: current status. 2008